BACKGROUND: The FibroTest and ActiTest are noninvasive biochemical markers of liver injury that are intended for use as alternatives to liver biopsy in patients with chronic hepatitis C. The aims of this study were to assess the quality of biopsy and the prevalence of discordances between biopsy and markers, to identify factors associated with discordances, and to attribute these discordances to either markers or biopsy failure. METHODS: Fibrosis stage and activity grade were prospectively assessed on the same day by a liver biopsy and by markers. On the basis of risk factors for failure and independent endpoints, discordance was classified as being attributable to biopsy or to markers. RESULTS: Only 74 of 537 patients (14%) had a biopsy size > or =25 mm. Discordance was observed in 154 of 537 patients (29%), including 16% for fibrosis staging and 17% for activity grading. Steatosis, an inflammatory profile, and biopsy size were associated with discordance. Discordance was attributable to failure of markers in 13 patients (2.4%) and to biopsy failure in 97 (18%; P <0.001 vs Fibrotest and Actitest), and was nonattributable in 44 patients (8.2%). The most frequent failures attributable to markers were false negatives (1.3%) attributable to inflammation. The most frequent failures attributable to biopsy were false negatives of activity grading (10.1%) and of fibrosis staging (4.5%), both associated with smaller biopsy size and steatosis. False positives of fibrosis staging (3.5%) were associated with fragmented biopsies. CONCLUSION: In this series, the size of liver biopsy is adequate in only a minor proportion (approximately 14%) of patients with chronic hepatitis C. When biopsy and marker results are discordant, a reason can be identified in more than two-thirds of cases and, in those cases, biopsy failure is >7 times more common than diagnostic failure of markers.
BACKGROUND: The FibroTest and ActiTest are noninvasive biochemical markers of liver injury that are intended for use as alternatives to liver biopsy in patients with chronic hepatitis C. The aims of this study were to assess the quality of biopsy and the prevalence of discordances between biopsy and markers, to identify factors associated with discordances, and to attribute these discordances to either markers or biopsy failure. METHODS:Fibrosis stage and activity grade were prospectively assessed on the same day by a liver biopsy and by markers. On the basis of risk factors for failure and independent endpoints, discordance was classified as being attributable to biopsy or to markers. RESULTS: Only 74 of 537 patients (14%) had a biopsy size > or =25 mm. Discordance was observed in 154 of 537 patients (29%), including 16% for fibrosis staging and 17% for activity grading. Steatosis, an inflammatory profile, and biopsy size were associated with discordance. Discordance was attributable to failure of markers in 13 patients (2.4%) and to biopsy failure in 97 (18%; P <0.001 vs Fibrotest and Actitest), and was nonattributable in 44 patients (8.2%). The most frequent failures attributable to markers were false negatives (1.3%) attributable to inflammation. The most frequent failures attributable to biopsy were false negatives of activity grading (10.1%) and of fibrosis staging (4.5%), both associated with smaller biopsy size and steatosis. False positives of fibrosis staging (3.5%) were associated with fragmented biopsies. CONCLUSION: In this series, the size of liver biopsy is adequate in only a minor proportion (approximately 14%) of patients with chronic hepatitis C. When biopsy and marker results are discordant, a reason can be identified in more than two-thirds of cases and, in those cases, biopsy failure is >7 times more common than diagnostic failure of markers.
Authors: M V Ragni; C G Moore; K Soadwa; M A Nalesnik; A B Zajko; A Cortese-Hassett; T L Whiteside; S Hart; A Zeevi; J Li; O S Shaikh Journal: Haemophilia Date: 2010-08-16 Impact factor: 4.287
Authors: J Macías; J A Girón-González; M González-Serrano; D Merino; P Cano; J A Mira; A Arizcorreta-Yarza; J Ruíz-Morales; J M Lomas-Cabeza; J A García-García; J E Corzo; J A Pineda Journal: Gut Date: 2005-08-23 Impact factor: 23.059
Authors: Gregory D Kirk; Jacquie Astemborski; Shruti H Mehta; Chuck Spoler; Cedric Fisher; Danisha Allen; Yvonne Higgins; Richard D Moore; Nezem Afdhal; Michael Torbenson; Mark Sulkowski; David L Thomas Journal: Clin Infect Dis Date: 2009-04-01 Impact factor: 9.079
Authors: Mahendra S Nehra; Ying Ma; Christopher Clark; Ruben Amarasingham; Don C Rockey; Amit G Singal Journal: J Clin Gastroenterol Date: 2013 May-Jun Impact factor: 3.062
Authors: Dalia Omran; Ayman Yosry; Samar K Darweesh; Mohammed M Nabeel; Mohammed El-Beshlawey; Sameh Saif; Azza Fared; Mohamed Hassany; Rania A Zayed Journal: Clin Exp Med Date: 2017-05-31 Impact factor: 3.984